GlaxoSmithKline has announced results from a 7-year safety and efficacy continuation study for Benlysta (belimumab) in patients with active, autoantibody-positive...
OptiScan Biomedical Corporation announced that the FDA has granted 510(k) clearance for the OptiScanner 5000 Glucose Monitoring System. The clearance...
Background: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in rheumatoid arthritis (RA).
The Janssen Pharmaceutical Companies of Johnson & Johnson announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase III TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC).
Novartis has announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant prostate cancer (mCRPC) versus standard of care alone. Many patients with mCRPC live with reduced physical functioning as well as significant pain.
Janssen Biotech announced the approval of a FDA Supplemental Biologics License Application (sBLA) for Simponi Aria (golimumab for infusion) for...